Successful therapy with rituximab in three patients with probable neurosarcoidosis
- \(\bf Background:\) Neurosarcoidosis occurs in about 5–15% of patients with sarcoidosis. Therapy with corticosteroids is generally accepted as the first-line medication, followed by various immunomodulating and cytotoxic agents or combined therapy. However, some patients show an unsatisfactory outcome or have adverse events and require novel treatment strategies. \(\bf Methods:\) We describe three patients with systemic sarcoidosis and central nervous system involvement who received CD20-targeted B-cell depletion with rituximab. \(\bf Results:\) Treatment with rituximab was well tolerated and followed by marked remission in patients nonresponsive to other immunosuppressive agents. \(\bf Conclusion:\) Rituximab may be used for patients with neurosarcoidosis who are nonresponsive to established treatment regimes.
| Author: | Maria Angela Samis-ZellaORCiDGND, Janina KneiphofGND, Aiden HaghikiaGND, Ralf GoldORCiDGND, Dirk WoitallaORCiDGND, Jan ThöneGND |
|---|---|
| URN: | urn:nbn:de:hbz:294-64388 |
| DOI: | https://doi.org/10.1177/1756286418805732 |
| Parent Title (German): | Therapeutic advances in neurological disorders |
| Document Type: | Article |
| Language: | English |
| Date of Publication (online): | 2019/05/17 |
| Date of first Publication: | 2018/10/26 |
| Publishing Institution: | Ruhr-Universität Bochum, Universitätsbibliothek |
| Tag: | Open Access Fonds B-cell depletion; CD-20; infliximab; neurosarcoidosis; sIL-2R |
| Volume: | 11 |
| First Page: | 1 |
| Last Page: | 5 |
| Note: | Article Processing Charge funded by the Deutsche Forschungsgemeinschaft (DFG) and the Open Access Publication Fund of Ruhr-Universität Bochum. |
| Institutes/Facilities: | St. Josef-Hospital Bochum, Neurologische Klinik |
| Dewey Decimal Classification: | Technik, Medizin, angewandte Wissenschaften / Medizin, Gesundheit |
| open_access (DINI-Set): | open_access |
| faculties: | Medizinische Fakultät |
| Licence (English): |  Creative Commons - CC BY-NC 4.0 - Attribution-NonCommercial 4.0 International |
